| Name | Title | Contact Details |
|---|
AllMed Healthcare Management is a utilization management and independent review organization providing comprehensive nurse and physician review solutions to payer and provider organizations nationwide. Our clients include leading health plans, medical management organizations, TPAs, disability carriers, hospital groups and ambulatory surgery centers. Services are deployed through PeerPoint, AllMed`s state-of-the-art medical review portal.
VHA Inc. is a national network of not-for-profit health care organizations working together to improve performance and efficiency in clinical, financial and operational management. Since 1977, when VHA established the first hospital membership organization, the company has applied its knowledge in analytics, contracting, consulting and network development to help members and customers achieve their strategic objectives. In 2012, VHA delivered $1.9 billion in savings and additional value to members. Serving 5,100 health system members and affiliates, VHA represents more than a quarter of the nation's hospitals. VHA also serves more than 118,000 non-acute health care customers enterprise-wide. VHA is based in Irving, Texas, and has 12 regional offices across the U.S. VHA, together with UHC, owns Novation, a supply chain company, and aptitude™ , the health care industry's first online direct contracting market. VHA also owns Provista, a supply chain company serving the non-acute market as well as hospitality, education and corporate markets.
Ulrich Medical Concepts is a Paducah, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Metamark Genetics, Inc. is a privately held biotechnology company founded in 2007 to develop novel, function-based, prognostic and diagnostic tests aimed at improving cancer care. The company's proprietary genomic and proteomic discovery platforms have yielded significant discoveries in several disease areas, including prostate, colon, and breast cancers. In early 2014, Metamark plans to commercialize ProMark™—its prostate cancer prognostic test—through its Cambridge, Massachusetts CLIA-certified laboratory. For more information, please visit the company's Website at www.metamarkgenetics.com. Metamark™ and ProMark™ are trademarks of Metamark Genetics, Inc.
WAVE Life Sciences is utilizing its innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, delivering exceptional treatment options for patients. Given the unique versatility of its chemistry platform, WAVE`s pipeline will span multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded RNAi.